HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study.

Abstract
Thirty-one evaluable adults with recurrent astrocytomas were treated with Cisplatin 35 mg/m2 I.V. daily for three days every 3-4 weeks. All patients had previously been irradiated and most had previously received chemotherapy. Approximately half had poor performance status. Two patients experienced complete remissions and two additional patients experienced partial remissions. Three patients stabilized. Gastrointestinal toxicity was generally mild. Further studies are planned of Cisplatin in combination with other agents.
AuthorsD J Stewart, R M O'Bryan, M Al-Sarraf, J J Costanzi, N Oishi
JournalJournal of neuro-oncology (J Neurooncol) Vol. 1 Issue 2 Pg. 145-7 ( 1983) ISSN: 0167-594X [Print] United States
PMID6088711 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Cisplatin
Topics
  • Adolescent
  • Adult
  • Aged
  • Astrocytoma (drug therapy)
  • Brain Neoplasms (drug therapy)
  • Cisplatin (administration & dosage, therapeutic use)
  • Drug Evaluation
  • Female
  • Glioblastoma (drug therapy)
  • Humans
  • Infusions, Parenteral
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: